AR098210A1 - COMBINATIONS OF INHIBITORS OF THE TUTOSINA QUINASA DE BRUTON AND IMMUNOTHERAPIES - Google Patents
COMBINATIONS OF INHIBITORS OF THE TUTOSINA QUINASA DE BRUTON AND IMMUNOTHERAPIESInfo
- Publication number
- AR098210A1 AR098210A1 ARP140104035A ARP140104035A AR098210A1 AR 098210 A1 AR098210 A1 AR 098210A1 AR P140104035 A ARP140104035 A AR P140104035A AR P140104035 A ARP140104035 A AR P140104035A AR 098210 A1 AR098210 A1 AR 098210A1
- Authority
- AR
- Argentina
- Prior art keywords
- inhibitor
- combinations
- btk
- immunotherapies
- bruton
- Prior art date
Links
Abstract
Combinaciones de inhibidores de la tirosina quinasa de Bruton (BTK), por ejemplo, 1-((R)-3-(4-amino-3-(4-fenoxifenil)-1H-pirazol[3,4-d]pirimidin-1-il)piperidin-1-il)prop-2-en-1-ona, con inmunoterapias. También se proveen métodos de tratamiento de cánceres y trastornos autoinmunes que comprenden administrar combinaciones de inhibidores de tirosina quinasa de Bruton (BTK), por ejemplo, 1-((R)-3-(4-amino-3-(4-fenoxifenil)-1H-pirazol[3,4-d]pirimidin-1-il)piperidin-1-il)prop-2-en-1-ona, y un inhibidor de un punto de control inmunológico. Reivindicación 1: Uso de una combinación que comprende un inhibidor de la BTK y un inhibidor de un punto de control inmunológico caracterizado porque es para el tratamiento de un cáncer. Reivindicación 10: Una combinación farmacéutica, caracterizada porque comprende: a) un inhibidor de la BTK; y b) un inhibidor de un punto de control inmunológico; y c) un excipiente farmacéuticamente aceptable.Bruton tyrosine kinase (BTK) inhibitor combinations, for example, 1 - ((R) -3- (4-amino-3- (4-phenoxyphenyl) -1H-pyrazole [3,4-d] pyrimidin- 1-yl) piperidin-1-yl) prop-2-en-1-one, with immunotherapies. Methods of treating cancers and autoimmune disorders are also provided which comprise administering combinations of Bruton tyrosine kinase inhibitors (BTK), for example, 1- ((R) -3- (4-amino-3- (4-phenoxyphenyl)) -1 H -pyrazol [3,4-d] pyrimidin-1-yl) piperidin-1-yl) prop-2-en-1-one, and an inhibitor of an immune control point. Claim 1: Use of a combination comprising a BTK inhibitor and an immune control point inhibitor characterized in that it is for the treatment of cancer. Claim 10: A pharmaceutical combination, characterized in that it comprises: a) a BTK inhibitor; and b) an inhibitor of an immune control point; and c) a pharmaceutically acceptable excipient.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361895988P | 2013-10-25 | 2013-10-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR098210A1 true AR098210A1 (en) | 2016-05-18 |
Family
ID=58700086
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP140104035A AR098210A1 (en) | 2013-10-25 | 2014-10-27 | COMBINATIONS OF INHIBITORS OF THE TUTOSINA QUINASA DE BRUTON AND IMMUNOTHERAPIES |
Country Status (1)
| Country | Link |
|---|---|
| AR (1) | AR098210A1 (en) |
-
2014
- 2014-10-27 AR ARP140104035A patent/AR098210A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12020552065A1 (en) | Ibrutinib combination therapy | |
| EA201690746A1 (en) | TREATMENT WITH THE USE OF BLUTON AND IMMUNOTHERAPY THYROZINKINASE INHIBITORS | |
| MX2021015370A (en) | Pharmaceutical formulations of bruton's tyrosine kinase inhibtor. | |
| MX2020014245A (en) | Inhibitors of cyclin-dependent kinases. | |
| BR112015021995A2 (en) | combinations of bruton tyrosine kinase inhibitors and cyp3a4 inhibitors | |
| CO7350624A2 (en) | Bruton tyrosine kinase inhibitors | |
| CY1122098T1 (en) | ISOCHROMENIUM DERIVATIVES AS PHOSPHOINOSITIDE-3 KINASE INHIBITORS | |
| BR112018077457A2 (en) | pharmaceutical composition to prevent or treat congenital hyperinsulinism and its method, hypoglycemia and its method, metabolic syndrome and its method and isolated peptide | |
| CR20160203A (en) | BRUTON TYPEOSIN CINASE INHIBITORS | |
| MX2017015574A (en) | Inhibitors of bruton's tyrosine kinase. | |
| ECSP21038390A (en) | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THE PREPARATION OF COMPOUNDS AND THEIR USE AS INHIBITORS OF KINASE ATR | |
| WO2014194254A9 (en) | Treatment of cancers using pi3 kinase isoform modulators | |
| BR112014030424A2 (en) | crystalline forms of a bruton tyrosine kinase inhibitor | |
| TW201613919A (en) | Inhibitors of Bruton's tyrosine kinase | |
| BR112019005046A2 (en) | therapeutic combinations comprising a raf inhibitor and an erk inhibitor | |
| MX2018001289A (en) | Combination therapies for treatment of cancer. | |
| CL2018002727A1 (en) | Medicine obtained by combining agonist fxr and arb | |
| PH12019502700A1 (en) | Methods for treating psoriasis using an anti-il-23 antibody | |
| CY1124316T1 (en) | CRYSTALLINE TOSYLATE SALT OF A PI3K DELTA SELECTIVE INHIBITOR FOR USE IN PHARMACEUTICAL PREPARATIONS | |
| MX2021010041A (en) | Pharmaceutical compositions comprising akt protein kinase inhibitors. | |
| ECSP16086247A (en) | (S) -PIRLINDOLE AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS FOR USE IN MEDICINE | |
| BR112019009029A2 (en) | anti-bag3 antibodies in combination with immune checkpoint inhibitors for therapeutic use | |
| MX2018013573A (en) | Certain protein kinase inhibitors. | |
| ECSP16086232A (en) | (R) -PIRLINDOLE AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS FOR USE IN MEDICINE | |
| BR112015012497A2 (en) | pharmaceutical combinations |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |